NOVA is the most capital-efficient drug screening platform 4.6M molecule submissions against 7K protein targets from a 1B+ compound library in just 4 months → the largest decentralized screening ever without upfront costs in compute and instant access to a cracked pool of

“we at METANOVA launched a subnet with the goal of fast-tracking the development of the most asymmetric real-world assets possible” and to: - design metaprogramming drugs that shape thought, emotion, behavior, define our health, and increase our sense of agency - advance

see you tomorrow 11 am UK time

in case you missed it 👇 our ceo Micaela on #bittensor revenue search with siamkidd and @markcreaser

Fantastic episode of Revenue Search with Micaela and @siamkidd – here’s what I learned about how METANOVA is reinventing drug discovery. Traditional pharma spends $2.6 billion and 10 years trying to develop each new drug. Nearly 90% of that effort fails before

the NOVA combinatorial dataset is now live 🔥 miners are already generating molecules using this dataset, like one of the 100 winners from our last challenge (see below). this marks the first in silico synthesis ever performed on-chain. we’re starting with reductive amination

🧬 NOVA target of the week: VMAT2 in mice 🐁 VMAT2 is responsible for packaging dopamine, serotonin, and norepinephrine into vesicles for release—key to mood, reward, movement, and hormonal signaling. it’s a clinically and commercially validated target: VMAT2 inhibitors like

reductive amination is the first reaction enabled in NOVA’s new combinatorial chemistry upgrade 🧪 it’s one of the most widely used reactions in drug discovery, key to making amines, which appear in over 75% of small-molecule drugs, including SSRIs, antipsychotics,

strategic and business implications of NOVA 💊 combinatorial update - stronger competitive moat a combinatorial engine makes NOVA more than a screen: it’s an exponentially scalable platform. this differentiates it from traditional docking workflows and adds defensibility to its

NOVA is a ticket for better medicines for a better you

NOVA💊 is expanding again! 40B+ new molecules coming monday 🧪 we’re adding 2 new reactions to our combinatorial dataset: • synthon-based triazoles • new click-amide cascade triazoles show up in antifungals, antivirals, cancer drugs, and more. they’re prized for stability &

🚨 VIDEO DROPPED 🎬 NOVA: Decentralized Drug Discovery Revolution 🧬 What is this? NOVA is Bittensor Subnet 68 - a decentralized drug discovery platform where AI miners compete to find breakthrough drug compounds The numbers are STAGGERING: 📊 5.5 MILLION molecule submissions

🧬 NOVA target of the week: SERT in humans → now screening from 44B+ molecules with the combinatorial dataset now live, miners are no longer limited to the 1B+ SAVI molecules, they can now generate novel compounds through in silico reactions, unlocking over 44B synthesizable

thank you for the s/o Dan in case you missed it: x.com/siamkidd/statu…

NOVA is adjusting miner emission rewards starting monday, we’ll burn 80% of miner rewards. this protects token health while aligning emissions with actual task complexity. miner emissions will scale back up as we increase the complexity of challenges and associated costs.

x.com/i/article/1945…

Mariuszek our intent is to do what is best for the long-term growth and value of the project including the token which supports our community and is used to reward miners. that is why we have minimized sell pressure both from our side and (inspired by templar) introduced this burn. we

📢 launching TREAT-2: targeting epigenetics for deeper healing this week we’re releasing TREAT-2, our second fine-tuned model on NOVA #bittensor #SN68 focused on a bold new class of targets: histone deacetylases (HDACs). HDACs represent a fundamentally different kind of drug

🧬 NOVA target of the week: HDAC2 in 🐀 HDAC2 is not your typical psych target. it doesn’t modulate dopamine, nor block serotonin, instead, it impacts how your brain stores memory and adapts to change. → associated with cognitive enhancement → involved in fear extinction

HDAC inhibitors might be the real smart drugs. new research shows the HDAC inhibitor CI-994 can prime the brain for learning: making neurons more responsive at the exact moment new memories are formed. like upgrading your brain’s “save” button: → stronger memory consolidation